Safe delivery in all climates

Getting vaccines to the people who need them most

We develop active vaccines as dry powders. Requiring no costly cold chain refrigeration, even in hot, remote areas, it means more vaccines getting through to the children who need them most.

Read more
Safe delivery in all climates

Developing new patents in dry-powder biologics

Our active dry-powder versions of Immunoglobulin G Antibody and Adenovirus were both air-dried at room temperature with high yield and little or no waste. We are now seeking patents.

Read more

Safe delivery in all climates

Blue sky biologics

Biologic therapies include many of the world’s most advanced treatments. Yet for many these injectable treatments remain inflexible and inconvenient to take on the move. We have a solution.

Read more
Safe delivery in all climates

From gentleness: strength

Our new, gently air-dried version of the Adenovirus vaccine component is truly tough. Remaining active even at 40°C, it could democratize vaccination delivery worldwide.

Read more

Delivering new, active, dry-powder vaccines and biologics

Ziccum is developing new dry-powder versions of the world’s most effective vaccines and biologic pharmaceuticals. These new, gently air-dried formulations can be transported easily and cost-effectively, with no costly cold storage or refrigeration required.

We’re cracking the Cold Chain

1-in-5 children worldwide still don’t receive even basic vaccines (WHO), and 1.5 million die every year from vaccine-preventable diseases. We have a solution. We develop active vaccines as dry powders. Dry powder formulations significantly reduce the cost of transporting and storing vaccines in a refrigerated Cold Chain in the critical last mile before administration. Read more

Developing new patents in dry-powder biologics

Virus-by-virus, protein-by-protein, we’re developing a new generation of unique dry-powder versions of many of the world’s most advanced biologics. We aim to seek patents on all of them. In a market forecast to be worth 25 BUSD by 2021, access to our patents will deliver a formidable competitive advantage. Read more

Blue sky biologics

New injectable biologic therapies are highly targeted and effective. Yet for many they remain unstable and inconvenient to transport and administer. One important reason is that 80% of biologics are still formulated as liquids. We have a solution. New dry-powder biologic treatments will be easier to both transport and take on the move—and more affordable. Read more

From gentleness: strength

Adenovirus is a central ingredient in vaccines being developed against Malaria, Ebola, meningitis and HIV. A dry powder version requiring no end-to-end refrigeration could democratize access to vaccines worldwide. Our dry powder Adenovirus stays active at 40°C for over a week. No refrigeration or freezing required. It is currently awaiting patent. Read more